(Reuters) -Biogen beat Wall Street estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 4% before the bell. The company also said its Alzheimer’s drug Leqembi, developed with Japanese partner Eisai, recorded global sales of about […]